PATENT CLAIM ANALYSIS

Application Number: 16146762
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-01
Patent Classification: ["424", "451000"]

Abstract:
The present invention relates generally to the field of using udenafil or a pharmaceutically acceptable salt thereof in patients who have undergone the Fontan operation.

Claim (Index 80):
Use of an effective dose of udenafil, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treat of a human patient, who has undergone Fontan palliation, for improving the human patient's exercise capacity, whose exercise capacity is adversely affected due to a decline in the human patient's heart function after Fontan palliation, wherein the human patient is in need of treatment to improve the human patient's exercise capacity as determined by maximum oxygen uptake a maximum exercise output (VO 2  measurement), and wherein the medicament is formulated for administration of a total daily dose of udenafil, or a pharmaceutically acceptable salt thereof, from about 125 mg to about 175 mg.

Metadata:
- Claim Count in Document: 287.0
- Percentile: 97.0
- Lexical Diversity: 1.04
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15887523', '14788211', '14079548', '15671653', '14442711']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7290623945328781
- 35 USC 102 Novelty (BERT): 0.6931025180399524
- Combined Prediction Score: 0.7254664068835855
- Mean Citation Score: 425.65413
- Max Citation Score: 788.03906
- Similarity Product: 686.1776449723386

Labels:
- Claim Label 101: 0
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 0

Dataset: test